Jan 29 (Reuters) – Thermo Fisher Scientific on Thursday beat Wall Street estimates for fourth-quarter profit and revenue on strong demand for its tools and services used in drug development by pharmaceutical clients.
Life sciences firms are benefiting from improving conditions in the pharmaceutical market and reduced policy uncertainty, helping them offset continued weakness in academic research funding.
Rival Danaher on Wednesday also posted better‑than‑expected fourth‑quarter results.
The company posted quarterly revenue of $12.22 billion, topping estimates of $11.95 billion, according to data compiled by LSEG.
Revenue for the analytical instrument segment rose more than 1% year-over-year to $2.22 billion, compared with analysts’ estimates of $2.19 billion, while sales in its laboratory products and biopharma services climbed nearly 8% to $6.38 billion.
Revenue from life sciences solutions, which provides products and services for drug discovery and manufacturing, grew 13% to $2.95 billion and specialty diagnostics brought in $1.22 billion, growing over 5%.
On an adjusted basis, the Massachusetts-based company earned $6.57 per share for the quarter ended December 31, 2025, compared with analysts’ average estimate of $6.45 per share.
(Reporting by Sahil Pandey and Puyaan Singh in Bengaluru; Editing by Vijay Kishore)
